rxstatShortages › Insulin Aspart

Insulin Aspart (Fiasp, Trurapi) shortage status

Shortage anticipated

Source: Health Canada shortage reports · Updated Jul 17, 2026

Also sold as: Fiasp, Trurapi, Novorapid, Kirsty

A shortage of Insulin Aspart is anticipated but not yet confirmed. 1 product(s) have anticipated-shortage reports on file with Health Canada.

A rapid-acting insulin used to control blood sugar at mealtimes in diabetes.

Products affected
0 / 8
Reports on file
16

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Anticipated
TRURAPI
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02506564
Resolved
TRURAPI
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02506564 · ended Jun 30, 2026
Resolved
TRURAPI
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02506572 · ended Jun 30, 2026
Resolved
KIRSTY
100UNIT · SOLUTION · BIOCON SDN.BHD
DIN 02520974 · ended Jun 9, 2026 · Demand increase for the drug.
Resolved
FIASP
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02460416 · ended Mar 24, 2026 · Demand increase for the drug.
Resolved
TRURAPI
100UNIT · SOLUTION · SANOFI-AVENTIS CANADA INC
DIN 02506572 · ended Jan 16, 2026
Discontinued
FIASP
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02460424
Resolved
FIASP
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02460408 · ended Jul 30, 2025 · Manufacturing issues preventing production/release. Alternate products available: NovoRapid® Vials, Fiasp® FlexTouch®
Resolved
FIASP
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02460408 · ended Oct 28, 2024 · Delay in shipping of the drug.
Resolved
FIASP
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02460408 · ended Oct 2, 2024 · Delay in shipping of the drug.
Resolved
NOVORAPID
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02245397 · ended Feb 5, 2024 · Disruption of the manufacture of the drug.
Discontinued
NOVORAPID
100UNIT · SOLUTION · NOVO NORDISK CANADA INC
DIN 02377209

Showing 12 of 16 reports. All reports are on file with Health Canada.

What's happening

A manufacturer has told Health Canada it expects supply of Insulin Aspart to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.

Insulin Aspart is classified under “INSULINS AND ANALOGUES” (ATC A10AB).

Recent changes

Common questions

What is Insulin Aspart used for?

A rapid-acting insulin used to control blood sugar at mealtimes in diabetes.

When will Insulin Aspart be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Insulin Aspart in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (insulins and analogues)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.